Cogent Biosciences Stock Debt To Equity
| COGT Stock | USD 7.29 0.10 1.35% |
Cogent Biosciences fundamentals help investors to digest information that contributes to Cogent Biosciences' financial success or failures. It also enables traders to predict the movement of Cogent Stock. The fundamental analysis module provides a way to measure Cogent Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cogent Biosciences stock.
Cogent |
Cogent Biosciences Company Debt To Equity Analysis
Cogent Biosciences' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Cogent Biosciences Debt To Equity | 0.09 % |
Most of Cogent Biosciences' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cogent Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Cogent Biosciences has a Debt To Equity of 0.087%. This is 99.84% lower than that of the Biotechnology sector and 99.55% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.82% higher than that of the company.
Cogent Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cogent Biosciences' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cogent Biosciences could also be used in its relative valuation, which is a method of valuing Cogent Biosciences by comparing valuation metrics of similar companies.Cogent Biosciences is currently under evaluation in debt to equity category among its peers.
Cogent Fundamentals
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 681.77 M | ||||
| Shares Outstanding | 113.85 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 99.85 % | ||||
| Number Of Shares Shorted | 10.8 M | ||||
| Price To Earning | (5.03) X | ||||
| Price To Book | 5.77 X | ||||
| Price To Sales | 1,321 X | ||||
| Gross Profit | (121.63 M) | ||||
| EBITDA | (275.94 M) | ||||
| Net Income | (255.86 M) | ||||
| Cash And Equivalents | 325.56 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 17.47 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 11.96 X | ||||
| Book Value Per Share | 1.32 X | ||||
| Cash Flow From Operations | (207.79 M) | ||||
| Short Ratio | 8.22 X | ||||
| Earnings Per Share | (1.98) X | ||||
| Price To Earnings To Growth | (0.14) X | ||||
| Target Price | 16.5 | ||||
| Number Of Employees | 205 | ||||
| Beta | 0.078 | ||||
| Market Capitalization | 840.78 M | ||||
| Total Asset | 327.9 M | ||||
| Retained Earnings | (859.48 M) | ||||
| Working Capital | 240.76 M | ||||
| Current Asset | 37.62 M | ||||
| Current Liabilities | 21.06 M | ||||
| Net Asset | 327.9 M |
About Cogent Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cogent Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cogent Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cogent Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.